Literature DB >> 28399386

Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung Cancer.

D Ross Camidge1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28399386      PMCID： PMC5791834          DOI： 10.1200/JOP.2017.022772

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  10 in total

1.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Authors:  Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

2.  A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.

Authors:  Karen L Reckamp; Vladislava O Melnikova; Chris Karlovich; Lecia V Sequist; D Ross Camidge; Heather Wakelee; Maurice Perol; Geoffrey R Oxnard; Karena Kosco; Peter Croucher; Errin Samuelsz; Cecile Rose Vibat; Shiloh Guerrero; Jennifer Geis; David Berz; Elaina Mann; Shannon Matheny; Lindsey Rolfe; Mitch Raponi; Mark G Erlander; Shirish Gadgeel
Journal:  J Thorac Oncol       Date:  2016-07-25       Impact factor: 15.609

3.  Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.

Authors:  Johan F Vansteenkiste; Jean-Luc Canon; Filippo De Braud; Francesco Grossi; Tommaso De Pas; Jhanelle E Gray; Wu-Chou Su; Enriqueta Felip; Hiroshige Yoshioka; Cesare Gridelli; Grace K Dy; Sumitra Thongprasert; Martin Reck; Paola Aimone; Gena Atalla Vidam; Pantelia Roussou; Ying A Wang; Emmanuelle Di Tomaso; Jean-Charles Soria
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

Review 4.  Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.

Authors:  Eric H Bernicker; Ross A Miller; Phillip T Cagle
Journal:  J Oncol Pract       Date:  2017-04       Impact factor: 3.840

5.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Authors:  David S Ettinger; Douglas E Wood; Wallace Akerley; Lyudmila A Bazhenova; Hossein Borghaei; David Ross Camidge; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Thomas J Dilling; M Chris Dobelbower; Ramaswamy Govindan; Mark Hennon; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Rudy P Lackner; Michael Lanuti; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; Neelesh Sharma; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2016-03       Impact factor: 11.908

6.  Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.

Authors:  Sinéad A Noonan; Lynne Berry; Xian Lu; Dexiang Gao; Anna E Barón; Patrick Chesnut; Jamie Sheren; Dara L Aisner; Dan Merrick; Robert C Doebele; Marileila Varella-Garcia; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2016-06-01       Impact factor: 15.609

7.  Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer.

Authors:  Evgeny N Imyanitov; Irina A Demidova; Marat G Gordiev; Maxim L Filipenko; Tatyana V Kekeyeva; Yuri K Moliaka; Polina A Gervas; Valeriy B Kozhemyako; Dmitriy I Vodolazhskiy; Liubov A Sergeyeva; Dinara U Fattakhova; Aglaya G Iyevleva; Natalia V Mitiushkina; Ekatherina Sh Kuligina; Alexey A Barinov; Meriiam S Mommaeva; Svetlana N Aleksakhina; Ilya V Tsimafeyeu; Sergey A Tjulandin
Journal:  Mol Diagn Ther       Date:  2016-08       Impact factor: 4.074

8.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2013-04-04       Impact factor: 5.568

9.  ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.

Authors:  Greta Alì; Agnese Proietti; Serena Pelliccioni; Cristina Niccoli; Cristiana Lupi; Elisa Sensi; Riccardo Giannini; Nicla Borrelli; Maura Menghi; Antonio Chella; Alessandro Ribechini; Federico Cappuzzo; Franca Melfi; Marco Lucchi; Alfredo Mussi; Gabriella Fontanini
Journal:  Arch Pathol Lab Med       Date:  2014-06-02       Impact factor: 5.534

10.  Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets.

Authors:  Juneko E Grilley-Olson; D Neil Hayes; Dominic T Moore; Kevin O Leslie; Matthew D Wilkerson; Bahjat F Qaqish; Michele C Hayward; Christopher R Cabanski; Xiaoying Yin; Mark A Socinski; Thomas E Stinchcombe; Leigh B Thorne; Timothy Craig Allen; Peter M Banks; Mary B Beasley; Alain C Borczuk; Philip T Cagle; Rebecca Christensen; Thomas V Colby; Georgean G Deblois; Göran Elmberger; Paolo Graziano; Craig F Hart; Kirk D Jones; Diane M Maia; C Ryan Miller; Keith V Nance; William D Travis; William K Funkhouser
Journal:  Arch Pathol Lab Med       Date:  2012-05-14       Impact factor: 5.534
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.